David Casebier, Ph.D. has been named vice president of Pharmaceutical Sciences at Wolfe Laboratories. Dr. Casebier will be responsible for strategic programs in R&D, focusing specifically on the innovation and growth of Wolfe’s proprietary analytical and formulation technology platforms.
Most recently, Dr. Casebier served as senior vice president for Pharmaceutical Sciences at Tokai Pharmaceuticals, where he successfully oversaw the formulation, development, and manufacturing of a novel therapeutic for prostate cancer. Previously, he was senior director of chemistry at Lantheus Medical Imaging, formerly a division of Bristol-Meyers Squibb. While at BMS, he was responsible for all aspects of chemistry from project conception to commercial launch, including medicinal chemistry and API manufacturing.
“We are excited for David to join Wolfe’s team,” said Janet Wolfe, Ph.D., founder and president of Wolfe Laboratories. “His proven ability to form and lead technically innovative teams is particularly timely as demand for Wolfe’s services increases amongst large biopharmaceutical companies. As Wolfe expands its capabilities in the areas of complex small molecule dosage forms, biologics, biosimilars, and targeted therapeutics, David’s wealth of drug development experience will accelerate the flow of technical innovation through the pipelines of our clients.”